A citation-based method for searching scientific literature

F Rode, K Almholt, M Petersen, M Kreilgaard, M Kjalke, D M Karpf, A V Groth, P B Johansen, L F Larsen, M Loftager, J Haaning. J Thromb Haemost 2018
Times Cited: 4







List of co-cited articles
17 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Emicizumab Prophylaxis in Hemophilia A with Inhibitors.
Johannes Oldenburg, Johnny N Mahlangu, Benjamin Kim, Christophe Schmitt, Michael U Callaghan, Guy Young, Elena Santagostino, Rebecca Kruse-Jarres, Claude Negrier, Craig Kessler,[...]. N Engl J Med 2017
466
75

Life in the shadow of a dominant partner: the FVIII-VWF association and its clinical implications for hemophilia A.
Steven W Pipe, Robert R Montgomery, Kathleen P Pratt, Peter J Lenting, David Lillicrap. Blood 2016
93
75

Pharmacokinetics, immunogenicity, safety, and preliminary efficacy of subcutaneous turoctocog alfa pegol in previously treated patients with severe hemophilia A (alleviate 1).
Robert Klamroth, Clemens Feistritzer, Ute Friedrich, Steven R Lentz, Kirsten Reichwald, Marek Zak, Pratima Chowdary. J Thromb Haemost 2020
7
75

Extended half-life pegylated, full-length recombinant factor VIII for prophylaxis in children with severe haemophilia A.
E S Mullins, O Stasyshyn, M T Alvarez-Román, D Osman, R Liesner, W Engl, M Sharkhawy, B E Abbuehl. Haemophilia 2017
44
50

An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia.
Alfica Sehgal, Scott Barros, Lacramioara Ivanciu, Brian Cooley, June Qin, Tim Racie, Julia Hettinger, Mary Carioto, Yongfeng Jiang, Josh Brodsky,[...]. Nat Med 2015
176
50

Hemostatic effect of a monoclonal antibody mAb 2021 blocking the interaction between FXa and TFPI in a rabbit hemophilia model.
Ida Hilden, Brian Lauritzen, Brit Binow Sørensen, Jes Thorn Clausen, Christina Jespersgaard, Berit Olsen Krogh, Andrew Neil Bowler, Jens Breinholt, Albrecht Gruhler, L Anders Svensson,[...]. Blood 2012
99
50

Targeting of Antithrombin in Hemophilia A or B with RNAi Therapy.
K John Pasi, Savita Rangarajan, Pencho Georgiev, Tim Mant, Michael D Creagh, Toshko Lissitchkov, David Bevan, Steve Austin, Charles R Hay, Inga Hegemann,[...]. N Engl J Med 2017
191
50

Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B.
Jerry S Powell, K John Pasi, Margaret V Ragni, Margareth C Ozelo, Leonard A Valentino, Johnny N Mahlangu, Neil C Josephson, David Perry, Marilyn J Manco-Johnson, Shashikant Apte,[...]. N Engl J Med 2013
232
50

A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model.
Takehisa Kitazawa, Tomoyuki Igawa, Zenjiro Sampei, Atsushi Muto, Tetsuo Kojima, Tetsuhiro Soeda, Kazutaka Yoshihashi, Yukiko Okuyama-Nishida, Hiroyuki Saito, Hiroyuki Tsunoda,[...]. Nat Med 2012
260
50

Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial.
P Chowdary, S Lethagen, U Friedrich, B Brand, C Hay, F Abdul Karim, R Klamroth, P Knoebl, M Laffan, J Mahlangu,[...]. J Thromb Haemost 2015
154
50

Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial.
Peter W Collins, Guy Young, Karin Knobe, Faraizah Abdul Karim, Pantep Angchaisuksiri, Claus Banner, Türkiz Gürsel, Johnny Mahlangu, Tadashi Matsushita, Eveline P Mauser-Bunschoten,[...]. Blood 2014
117
50

Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial.
Elena Santagostino, Uri Martinowitz, Toshko Lissitchkov, Brigitte Pan-Petesch, Hideji Hanabusa, Johannes Oldenburg, Lisa Boggio, Claude Negrier, Ingrid Pabinger, Mario von Depka Prondzinski,[...]. Blood 2016
115
50

Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A.
Johnny Mahlangu, Jerry S Powell, Margaret V Ragni, Pratima Chowdary, Neil C Josephson, Ingrid Pabinger, Hideji Hanabusa, Naresh Gupta, Roshni Kulkarni, Patrick Fogarty,[...]. Blood 2014
308
50


Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A.
A Tiede, B Brand, R Fischer, K Kavakli, S R Lentz, T Matsushita, C Rea, K Knobe, D Viuff. J Thromb Haemost 2013
116
50

Guidelines for the management of hemophilia.
A Srivastava, A K Brewer, E P Mauser-Bunschoten, N S Key, S Kitchen, A Llinas, C A Ludlam, J N Mahlangu, K Mulder, M C Poon,[...]. Haemophilia 2013
50


Recombinant factor VIII Fc fusion protein for immune tolerance induction in patients with severe haemophilia A with inhibitors-A retrospective analysis.
M Carcao, A Shapiro, J M Staber, N Hwang, C Druzgal, K Lieuw, M Belletrutti, C D Thornburg, S P Ahuja, J Morales-Arias,[...]. Haemophilia 2018
29
25

Men with severe hemophilia in the United States: birth cohort analysis of a large national database.
Marshall A Mazepa, Paul E Monahan, Judith R Baker, Brenda K Riske, J Michael Soucie. Blood 2016
71
25


Effects of the factor V G1691A mutation and the factor II G20210A variant on the clinical expression of severe hemophilia A in children--results of a multicenter studys.
Karin Kurnik, Wolfhart Kreuz, Sylvia Horneff, Christine Düring, Rosemarie Schobess, Christoph Bidlingmaier, Carmen Escuriola Ettingshausen, Anne Krümpel, Nadia Bogdanova, Ulrike Nowak-Göttl. Haematologica 2007
36
25

Small peptides blocking inhibition of factor Xa and tissue factor-factor VIIa by tissue factor pathway inhibitor (TFPI).
Michael Dockal, Rudolf Hartmann, Markus Fries, M Christella L G D Thomassen, Alexandra Heinzmann, Hartmut Ehrlich, Jan Rosing, Frank Osterkamp, Thomas Polakowski, Ulrich Reineke,[...]. J Biol Chem 2014
36
25

Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B.
I M Nilsson, E Berntorp, T Löfqvist, H Pettersson. J Intern Med 1992
741
25



Therapeutic choices for patients with hemophilia and high-titer inhibitors.
R Kulkarni, L M Aledort, E Berntorp, H H Brackman, D Brown, A R Cohen, N P Ewing, A Gringeri, R Gruppo, K Hoots,[...]. Am J Hematol 2001
47
25

Factor VIII-Mimetic Function of Humanized Bispecific Antibody in Hemophilia A.
Midori Shima, Hideji Hanabusa, Masashi Taki, Tadashi Matsushita, Tetsuji Sato, Katsuyuki Fukutake, Naoki Fukazawa, Koichiro Yoneyama, Hiroki Yoshida, Keiji Nogami. N Engl J Med 2016
241
25

Aptamer ARC19499 mediates a procoagulant hemostatic effect by inhibiting tissue factor pathway inhibitor.
Emily K Waters, Ryan M Genga, Michael C Schwartz, Jennifer A Nelson, Robert G Schaub, Karen A Olson, Jeffrey C Kurz, Kathleen E McGinness. Blood 2011
96
25

Nonacog beta pegol (N9-GP) in haemophilia B: A multinational phase III safety and efficacy extension trial (paradigm™4).
Guy Young, Peter W Collins, Torben Colberg, Ampaiwan Chuansumrit, Hideji Hanabusa, Steven R Lentz, Johnny Mahlangu, Evelien P Mauser-Bunschoten, Claude Négrier, Johannes Oldenburg,[...]. Thromb Res 2016
38
25

Therapeutic applications of hydrogels in oral drug delivery.
Lindsey A Sharpe, Adam M Daily, Sarena D Horava, Nicholas A Peppas. Expert Opin Drug Deliv 2014
119
25

New therapies for hemophilia.
Steven W Pipe. Hematology Am Soc Hematol Educ Program 2016
18
25

Targeting activated protein C to treat hemophilia.
Stéphanie G I Polderdijk, Trevor P Baglin, James A Huntington. Curr Opin Hematol 2017
23
25

Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A.
P W Collins, V S Blanchette, K Fischer, S Björkman, M Oh, S Fritsch, P Schroth, G Spotts, J Astermark, B Ewenstein. J Thromb Haemost 2009
242
25

Immunogenicity, efficacy and safety of Nuwiq® (human-cl rhFVIII) in previously untreated patients with severe haemophilia A-Interim results from the NuProtect Study.
R J Liesner, M Abashidze, O Aleinikova, C Altisent, M J Belletrutti, A Borel-Derlon, M Carcao, H Chambost, A K C Chan, L Dubey,[...]. Haemophilia 2018
18
25

Outcome of Clinical Trials with New Extended Half-Life FVIII/IX Concentrates.
Maria Elisa Mancuso, Elena Santagostino. J Clin Med 2017
57
25


Design and characterization of an APC-specific serpin for the treatment of hemophilia.
Stéphanie G I Polderdijk, Ty E Adams, Lacramioara Ivanciu, Rodney M Camire, Trevor P Baglin, James A Huntington. Blood 2017
81
25


Absence of hematopoietic tissue factor pathway inhibitor mitigates bleeding in mice with hemophilia.
Susan A Maroney, Brian C Cooley, Josephine P Ferrel, Catherine E Bonesho, Lone V Nielsen, Peter B Johansen, Mette B Hermit, Lars C Petersen, Alan E Mast. Proc Natl Acad Sci U S A 2012
63
25

A factor VIII-nanobody fusion protein forming an ultrastable complex with VWF: effect on clearance and antibody formation.
Vincent Muczynski, Caterina Casari, François Moreau, Gabriel Aymé, Charlotte Kawecki, Paulette Legendre, Valerie Proulle, Olivier D Christophe, Cécile V Denis, Peter J Lenting. Blood 2018
12
25



Antithrombin affects hemostatic response to recombinant activated factor VII in factor VIII deficient plasma.
Fania Szlam, Taro Taketomi, Chelsea A Sheppard, Christine L Kempton, Jerrold H Levy, Kenichi A Tanaka. Anesth Analg 2008
16
25

Anti-factor IXa/X bispecific antibody (ACE910): hemostatic potency against ongoing bleeds in a hemophilia A model and the possibility of routine supplementation.
A Muto, K Yoshihashi, M Takeda, T Kitazawa, T Soeda, T Igawa, Y Sakamoto, K Haraya, Y Kawabe, M Shima,[...]. J Thromb Haemost 2014
68
25


Magnetic resonance imaging and ultrasound evaluation of "healthy" joints in young subjects with severe haemophilia A.
M N D Di Minno, S Iervolino, E Soscia, A Tosetto, A Coppola, M Schiavulli, E Marrone, C Ruosi, M Salvatore, G Di Minno. Haemophilia 2013
44
25

Oral Tolerance Induction in Hemophilia B Dogs Fed with Transplastomic Lettuce.
Roland W Herzog, Timothy C Nichols, Jin Su, Bei Zhang, Alexandra Sherman, Elizabeth P Merricks, Robin Raymer, George Q Perrin, Mattias Häger, Bo Wiinberg,[...]. Mol Ther 2017
39
25


In vitro studies show synergistic effects of a procoagulant bispecific antibody and bypassing agents.
R Hartmann, T Feenstra, L Valentino, M Dockal, F Scheiflinger. J Thromb Haemost 2018
43
25

A Pharmacometric Approach to Substitute for a Conventional Dose-Finding Study in Rare Diseases: Example of Phase III Dose Selection for Emicizumab in Hemophilia A.
Koichiro Yoneyama, Christophe Schmitt, Naoki Kotani, Gallia G Levy, Ryu Kasai, Satofumi Iida, Midori Shima, Takehiko Kawanishi. Clin Pharmacokinet 2018
44
25


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.